Q. Xia

发表

Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study

Q. Ning, Chuanlong Zhu, Yongping Chen, 2019, Hepatology International.

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

R. Verona, V. Moreno, E. Calvo, 2022, Investigational New Drugs.

Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data.

G. Mayhew, William Y. Kim, A. Hartmann, 2020 .

A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.

J. Gschwend, A. Santiago-Walker, B. Tran, 2020 .

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

A. Vannucchi, J. Mascarenhas, R. Komrokji, 2021, Annals of Hematology.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

R. Figlin, K. Flaherty, S. Srinivas, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.

V. Moreno, E. Calvo, P. Hellemans, 2019, Journal of Clinical Oncology.

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab

M S Brown, T. Cloughesy, J. Goldin, 2011, Neurology.

TLR-MEDIATED SUPPRESSION OF THE CCL22-CCR4 AXIS AS A NEW TARGET FOR TUMOR IMMUNOTHERAPY

H. Feng, Q. Xia, 2021 .

Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer

M. Socinski, C. Langer, Y. Oh, 2008 .

Safety of Bevacizumab Therapy in Subjects with Brain Metastases due to Non–Small-Cell Lung Cancer (NSCLC)

J. Hainsworth, Y. Oh, J. Huang, 2007 .

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

Shuijun Zhang, P. Bie, S. Ye, 2018, BMC Cancer.

Sequential combination therapy with IFN, rhIL-2 and therapeutic vaccine enhanced HBsAg loss in entecavir-suppressed CHB patients (the Endeavor study): an interim analysis

Q. Ning, Lai Wei, Jianning Jiang, 2017 .

Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.

G. Iyer, J. Tabernero, G. Folprecht, 2023, Journal of Clinical Oncology.